DENNIS WESTIN: Open Payments
NPI 1992705388 · TUCSON, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$210 in 10 payments from 7 companies in 2025. Trend: 2023 $260 · 2024 $216 · 2025 $210
Food & beverage: $210
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 2 | $44 |
| Teva Pharmaceuticals USA, Inc. | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Neurocrine BioSciences, Inc. | 1 | $26 |
| E.R. Squibb & Sons, L.L.C. | 1 | $23 |
| Almatica Pharma LLC | 1 | $22 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $18 |
Products named: VRAYLAR, AUSTEDO XR, TRINTELLIX, INGREZZA, COBENFY, LOREEV XR, CAPLYTA.
Industry payments across AZ — which companies pay providers there.
